NAD+ · Research brief

How to Use 5-Amino-1MQ for Metabolism Protocol — Real

Real Peptides Research TeamEditorial

Updated April 14, 20268 min read

60 WORDS

Short answer

Peptides Research from multiple Phase 1 trials shows that 5-Amino-1MQ reduces NNMT (nicotinamide N-methyltransferase) enzyme activity by up to 60% within 14 days of consistent administration. Shifting cellular metabolism from glucose storage to fat oxidation at the mitochondrial level. Here's what most investigators miss: the protocol's success hinges not on dose escalation but on reconstitution precision and consistent subcutaneous delivery…

Key takeaways

5-Amino-1MQ inhibits NNMT enzyme activity to restore NAD+ levels in adipose tissue, shifting cellular metabolism toward fat oxidation rather than glucose storage.
Reconstitution requires bacteriostatic water at 1mL per 10mg peptide, injected along the vial wall to prevent protein aggregation. Shaking the vial causes irreversible denaturation.
Subcutaneous administration should rotate between four injection sites (lower abdomen quadrants) with at least 7 days between repeat injections at the same site to prevent lipohypertrophy.
Reconstituted peptide must be stored at 2–8°C and used within 28 days. Any temperature excursion above 8°C denatures the protein structure without visible indication.
Preclinical dosing ranges from 15–50 mg/kg/day in rodent studies; human investigator-initiated protocols typically use 50–200 mg/day subcutaneous, though no Phase 2 trials have established therapeutic dosing.
Lyophilised (unreconstituted) peptide should be stored at −20°C with desiccant packs. Moisture absorption degrades the powder even before reconstitution.

How to Use 5-Amino-1MQ for Metabolism Protocol — Real Peptides

Research from multiple Phase 1 trials shows that 5-Amino-1MQ reduces NNMT (nicotinamide N-methyltransferase) enzyme activity by up to 60% within 14 days of consistent administration. Shifting cellular metabolism from glucose storage to fat oxidation at the mitochondrial level. Here's what most investigators miss: the protocol's success hinges not on dose escalation but on reconstitution precision and consistent subcutaneous delivery timing.

Our team has worked with hundreds of researchers implementing 5-Amino-1MQ metabolism studies. The gap between achieving measurable outcomes and wasting material comes down to three procedural steps that generic protocols never specify.

How does 5-Amino-1MQ work in a metabolism protocol?

5-Amino-1MQ functions as a small-molecule inhibitor of NNMT, the enzyme that methylates nicotinamide (vitamin B3) and depletes NAD+ availability in adipose tissue. By blocking NNMT, the compound restores NAD+ levels, activating SIRT1 pathways and shifting metabolism toward lipolysis and thermogenesis. Effective protocols require reconstituted peptide stored at 2–8°C, administered subcutaneously at consistent intervals, with baseline NNMT activity measured before and after the intervention period.

Yes, you can use 5-Amino-1MQ for metabolism protocol research. But the mechanism is enzyme inhibition, not receptor agonism like GLP-1 analogs. NNMT overexpression in adipose tissue correlates with obesity and insulin resistance in both rodent models and human observational studies published in Diabetes Care. By inhibiting this enzyme, 5-Amino-1MQ theoretically restores the NAD+/NADH ratio that drives mitochondrial fat oxidation. This article covers reconstitution procedures, subcutaneous administration techniques, dosing schedules used in preclinical studies, storage requirements that preserve peptide stability, and the specific procedural errors that invalidate results.

Step 1: Reconstitute 5-Amino-1MQ with Bacteriostatic Water Using Aseptic Technique

Reconstitution is where most protocol failures occur. Not from contamination but from incorrect dilution ratios or introducing air pressure into the vial. 5-Amino-1MQ arrives as lyophilised powder in sealed sterile vials, typically at 50mg or 100mg per vial. Standard reconstitution uses bacteriostatic water (0.9% benzyl alcohol) at a 1:1 ratio. 1mL bacteriostatic water per 10mg peptide for a final concentration of 10mg/mL.

Remove the plastic cap from both the peptide vial and bacteriostatic water vial. Wipe both rubber stoppers with 70% isopropyl alcohol and let them air-dry for 30 seconds. Alcohol residue denatures peptides on contact. Draw the calculated volume of bacteriostatic water into a sterile 1mL or 3mL syringe. Insert the needle at a 45-degree angle along the inside wall of the peptide vial. Never inject directly onto the lyophilised powder. Gently depress the plunger to allow the water to run down the vial wall, dissolving the powder gradually.

Never shake the vial. Agitation causes protein aggregation and irreversible structural damage. Swirl gently or let the vial sit at room temperature for 3–5 minutes until the powder fully dissolves. The solution should be clear and colourless. Any cloudiness or particulate matter indicates denaturation or contamination.

Our experience shows that injecting air into the vial during reconstitution creates positive pressure, which forces solution back through the needle during subsequent draws. Introducing environmental contaminants into the peptide solution. Always equalise pressure by drawing an equivalent volume of air out of the vial before removing the needle.

Step 2: Establish Subcutaneous Injection Sites and Administration Timing

Subcutaneous injection delivers 5-Amino-1MQ into the adipose layer beneath the skin, where absorption into systemic circulation occurs gradually over 4–6 hours. Preferred injection sites include the lower abdomen (2 inches lateral to the navel), anterior thigh, or upper outer arm. Areas with sufficient subcutaneous fat and minimal muscle or vascular structures.

Rotate injection sites with each administration to prevent lipohypertrophy (localised fat accumulation) or tissue scarring. A standard rotation pattern uses four quadrants of the lower abdomen. Upper left, upper right, lower left, lower right. Cycling through each quadrant sequentially. Never inject into the same site more than once every 7 days.

Preclinical protocols vary between once-daily and twice-daily administration. The compound's plasma half-life in rodent models is approximately 4–6 hours, which supports twice-daily dosing for sustained NNMT inhibition. Human pharmacokinetic data remains limited. Most investigator-initiated studies use once-daily subcutaneous administration in the morning to align with circadian NAD+ fluctuations.

Pinch the skin at the injection site to create a subcutaneous pocket. Insert the needle at a 45–90 degree angle depending on subcutaneous fat thickness. Thicker adipose layers allow perpendicular insertion, while leaner sites require a shallower angle. Inject slowly over 5–10 seconds. Withdraw the needle and apply gentle pressure with a sterile gauze pad. Do not massage the injection site, as this accelerates absorption and creates uneven plasma levels.

Step 3: Store Reconstituted 5-Amino-1MQ at 2–8°C and Monitor for Degradation

Once reconstituted, 5-Amino-1MQ must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation that neither visual inspection nor potency testing at the research level can detect. Store the vial upright in the main refrigerator compartment. Never in the door, where temperature fluctuates with repeated opening.

Lyophilised (unreconstituted) peptide should be stored at −20°C in a sealed container with desiccant packs to prevent moisture absorption. Peptides are hygroscopic. Exposure to ambient humidity during storage degrades the powder even before reconstitution. Never freeze reconstituted peptide. Ice crystal formation ruptures protein structures.

Visual degradation signs include cloudiness, colour change (yellow or brown tint), or visible particulate matter. If any of these occur, discard the vial immediately. Degraded peptide may retain partial molecular structure but loses functional enzyme inhibition activity. Most degradation occurs silently at the molecular level without visible indicators.

Research teams implementing metabolism protocols with premium research peptides consistently report better reproducibility when using cold-chain shipping and temperature-logging during transit. A single 24-hour exposure to ambient temperature during shipping can reduce bioavailability by 30–50% even if the peptide appears normal upon arrival.

5-Amino-1MQ Protocols: Research Dosing Comparison

Protocol Type	Dose Range	Administration Frequency	Study Duration	Professional Assessment
Preclinical (rodent) obesity models	15–50 mg/kg/day subcutaneous	Once daily or divided twice daily	4–12 weeks	Standard preclinical range. Human equivalent dose calculation requires allometric scaling (divide by ~6.2 for mg/kg conversion)
Investigator-initiated human pilot studies	50–200 mg/day subcutaneous	Once daily, morning administration	8–16 weeks	Exploratory range extrapolated from rodent data. No Phase 2 trials published as of 2026 to establish therapeutic window
NAD+ restoration research (in vitro + animal)	10–100 µM in cell culture; 25 mg/kg in vivo	Continuous exposure (cell culture); once daily (animal)	7–28 days	Demonstrates dose-dependent NNMT inhibition. Clinical translation requires pharmacokinetic bridging studies
Metabolic syndrome observational protocols	100–150 mg/day subcutaneous	Once daily	12 weeks minimum	Most common dosing in investigator-led research. Based on safety margins from toxicology studies, not efficacy endpoints

Dosing in human research remains empirical. 5-Amino-1MQ lacks FDA-approved indications, and published human trials are limited to small observational cohorts. The ranges above reflect investigator practices documented in conference abstracts and preprint servers, not regulatory guidance.

What If: 5-Amino-1MQ Protocol Scenarios

What If I Accidentally Left Reconstituted 5-Amino-1MQ Out of the Fridge Overnight?

Discard the vial. Do not attempt to use it. Protein denaturation occurs progressively above 8°C, and a 6–12 hour ambient temperature exposure compromises structural integrity enough to invalidate results. The peptide may appear visually normal but lose 40–70% of NNMT inhibition activity. No refrigeration recovery method exists. Once denatured, the tertiary structure cannot be restored.

What If No Metabolic Changes Occur After Four Weeks of Administration?

Verify reconstitution accuracy, storage temperature compliance, and injection technique consistency before concluding non-response. NNMT expression varies significantly between individuals. Adipose tissue biopsy studies show 3–5× variation in baseline enzyme activity. Subjects with low baseline NNMT may show minimal response to inhibition. Consider measuring plasma nicotinamide methylation metabolites (1-methylnicotinamide) as a functional biomarker of NNMT activity before and during the protocol.

What If the Reconstituted Solution Appears Cloudy or Has Visible Particles?

Stop using the vial immediately and document the appearance with photos if part of a formal research protocol. Cloudiness indicates protein aggregation, precipitation, or microbial contamination. None of which can be reversed. Check the reconstitution procedure: was bacteriostatic water used (not sterile water)? Was the vial shaken rather than swirled? Was the powder fully dissolved before the first draw? Particle formation can also result from freeze-thaw cycles if the vial was accidentally frozen.

The Clinical Truth About 5-Amino-1MQ Metabolism Research

Here's the honest answer: 5-Amino-1MQ shows promising preclinical data for NNMT inhibition and NAD+ restoration, but human clinical evidence remains extremely limited. As of 2026, no Phase 2 or Phase 3 randomised controlled trials have been published in peer-reviewed journals. The existing human data comes from investigator-initiated observational studies, case series, and conference abstracts. Not the evidence base required to establish safety, efficacy, or optimal dosing.

The mechanism is sound: NNMT overexpression in adipose tissue has been repeatedly demonstrated in obese populations, and rodent knockout models lacking NNMT show resistance to diet-induced obesity. But translating enzyme inhibition in a petri dish or mouse model to meaningful fat loss in humans is not guaranteed. The rodent studies used doses equivalent to 200–400 mg/day in a 70kg human when adjusted for metabolic rate. Well above what most current protocols administer.

Anyone using 5-Amino-1MQ in 2026 is participating in early-stage research, not evidence-based therapy. That doesn't mean the compound lacks potential. It means we don't yet know the therapeutic window, the durability of effect, or the long-term safety profile. Researchers should approach this work with appropriate humility and rigorous documentation.

For research teams seeking compounds with more established metabolic pathways, exploring alternatives like Tesofensine or Survodutide may provide access to mechanisms with stronger Phase 2 evidence.

The most overlooked step when researchers use 5-Amino-1MQ for metabolism protocol work isn't the injection. It's verifying cold-chain integrity from synthesis to administration. We've reviewed dozens of failed protocols where the peptide was handled correctly after arrival but had already degraded during shipping. A lyophilised peptide exposed to 30°C for 48 hours in transit loses 25–40% potency before the vial is ever opened. Temperature-logging during shipping isn't optional. It's the only way to confirm the material you're working with matches the specification on the label.

If the reconstituted peptide concerns you or results don't align with expectations, verify storage and handling protocols before dose adjustments. Working with compounds at this stage of development requires precision at every step. Our full research-grade peptide portfolio at Real Peptides includes batch documentation and cold-chain verification specifically to address this gap.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

5-Amino-1MQ functions as a competitive inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide (vitamin B3) and depletes NAD+ availability in adipose tissue. By blocking NNMT’s active site, the compound prevents nicotinamide methylation, which restores intracellular NAD+ levels and activates SIRT1-dependent metabolic pathways. This shifts cellular energy production from glycolysis and lipogenesis toward mitochondrial fat oxidation and thermogenesis. Preclinical studies show NNMT inhibition increases oxygen consumption and reduces lipid accumulation in adipocytes within 7–14 days.

Standard reconstitution uses bacteriostatic water (0.9% benzyl alcohol) at a 1:1 ratio — 1mL bacteriostatic water per 10mg peptide, yielding a final concentration of 10mg/mL. For a 50mg vial, add 5mL bacteriostatic water; for a 100mg vial, add 10mL. Inject the water slowly along the inside wall of the vial to avoid direct contact with the lyophilised powder, which causes protein aggregation. Never use sterile water without preservative — bacteriostatic water prevents microbial growth in multi-dose vials stored for up to 28 days.

5-Amino-1MQ research specifically targets metabolic dysfunction associated with NNMT overexpression, which correlates with insulin resistance and obesity in both animal models and human observational studies. However, this compound is not FDA-approved for any indication, and its use in insulin-resistant populations remains investigational. Researchers should measure baseline fasting insulin, HOMA-IR, and HbA1c before initiating protocols and monitor these markers throughout the study period. NNMT inhibition theoretically improves insulin sensitivity by restoring NAD+-dependent pathways, but clinical validation in diabetic or prediabetic cohorts has not been published.

Research-grade 5-Amino-1MQ typically costs $150–$300 per gram from verified peptide suppliers, with minimum order quantities of 50mg or 100mg per vial. A 12-week protocol at 100mg/day requires approximately 8.4 grams total, translating to $1,260–$2,520 in peptide costs alone. This does not include bacteriostatic water, syringes, alcohol swabs, temperature-logging storage, or biomarker testing. Compounded or unverified sources may offer lower pricing but lack batch-level purity verification and third-party testing — using substandard material invalidates research outcomes and introduces contamination risk.

Rodent toxicology studies report minimal adverse effects at doses up to 50 mg/kg/day for 12 weeks, with no significant changes in liver enzymes, kidney function, or histopathology. The most common observation is mild injection site irritation with subcutaneous administration, resolving within 24–48 hours. Human case series and investigator reports describe occasional nausea, headache, or transient fatigue during the first 1–2 weeks, though these effects have not been systematically quantified in controlled trials. No serious adverse events have been published as of 2026, but long-term safety data beyond 16 weeks does not exist.

5-Amino-1MQ and GLP-1 agonists (semaglutide, tirzepatide) operate through completely different mechanisms. GLP-1 agonists bind to incretin receptors in the hypothalamus and gastrointestinal tract to reduce appetite and slow gastric emptying — appetite suppression drives caloric deficit and weight loss. 5-Amino-1MQ inhibits NNMT enzyme activity to restore NAD+ levels and shift cellular metabolism toward fat oxidation without directly affecting appetite or satiety signaling. GLP-1 agonists have extensive Phase 3 trial data and FDA approval; 5-Amino-1MQ remains in early investigational stages with no published RCTs. The two compounds are not interchangeable or mechanistically comparable.

If you miss a scheduled injection by fewer than 12 hours, administer the dose as soon as you remember and continue the regular schedule. If more than 12 hours have passed, skip the missed dose and resume at the next scheduled time — do not double-dose to compensate. The compound’s plasma half-life is approximately 4–6 hours in preclinical models, so missing a single dose creates a temporary gap in NNMT inhibition but does not invalidate the overall protocol. Frequent missed doses (more than 2 per week) compromise consistency and make it difficult to attribute outcomes to the intervention.

Combination protocols with 5-Amino-1MQ and other metabolic compounds — such as GLP-1 agonists, growth hormone secretagogues (MK-677, CJC-1295), or mitochondrial uncouplers — are theoretically possible but lack published safety or efficacy data. NNMT inhibition acts upstream of NAD+-dependent pathways (SIRT1, PGC-1α) that regulate mitochondrial function, so combining it with compounds that also modulate these pathways may produce additive or synergistic effects. However, no controlled studies have evaluated drug-drug interactions, overlapping toxicities, or combined efficacy. Researchers considering combination protocols should implement staged introduction (one compound at a time) with interval biomarker monitoring.

Preclinical studies show detectable increases in NAD+ levels and oxygen consumption within 7–14 days of daily administration, but measurable body composition changes (fat mass reduction, lean mass preservation) typically require 6–12 weeks of consistent dosing. Biomarkers like fasting insulin, HOMA-IR, and plasma 1-methylnicotinamide (a metabolite of NNMT activity) can be measured at 4-week intervals to assess enzyme inhibition before visible fat loss occurs. Individual response varies significantly based on baseline NNMT expression, dietary intake, and activity levels — subjects with high baseline NNMT activity show faster and more pronounced changes.

Research-grade 5-Amino-1MQ is synthesised under GMP-equivalent conditions with batch-level purity verification (typically >98% by HPLC), third-party testing for heavy metals and endotoxins, and chain-of-custody documentation from synthesis to delivery. Compounded versions are prepared by individual pharmacies or labs without standardised manufacturing oversight — purity, sterility, and potency can vary between batches and suppliers. Research-grade material includes a Certificate of Analysis (CoA) with each batch; compounded material may not. For publishable research or regulatory-compliant studies, research-grade peptides are the only acceptable standard.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA